Healthcare / BiotechnologyOslo
$10.00
+0.10 (+1.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-70.4M · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$769M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-97.1%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-60.0M · FCF $-59.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $11.1M | $4.0M | $11.0M |
| Net Income | $-60.0M | $-60.0M | $-94.3M | $-87.9M | $-56.1M |
| EBITDA | $-58.8M | $-58.8M | $-93.2M | $-86.9M | $-55.0M |
| EPS | — | — | -1.73 | -2.18 | -1.40 |
| Operating Margin | — | — | -861.4% | -2425.1% | -595.3% |
| Net Margin | — | — | -846.7% | -2202.4% | -508.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.02 | 0.01 | 0.01 |
| Current Ratio | 4.28 | 4.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-59.9M | $-59.9M | $-70.4M | $-96.0M | $-52.8M |
| Returns | |||||
| ROE | -97.1% | -97.1% | -87.4% | -171.3% | -41.5% |
| Valuation | |||||
| P/B | 11.11 | 11.11 | 2.96 | 5.92 | 2.14 |
| Growth & Yield | |||||
| Revenue Growth | — | — | 179.0% | -63.8% | — |
| EPS Growth | — | — | 20.5% | -55.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.73 → n/d
Residual
+22.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.